ReviewBJR open2026
Current state of the art of new prostate MRI technologies and potential future developments.
Review in BJR open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer is a common malignancy in men. With the advent of multiparametric MRI and the Prostate Imaging-Reporting and Data System (PI-RADS) framework for grading lesions, there have been multiple advancements in the management and treatment of the disease. There are several new advancements in prostate MRI technology that suggest further exciting developments in the field, ranging from novel imaging sequences to the application of machine learning methods and artificial intelligence (AI) across the imaging pipeline. In this review, we aim to provide context on the current advancements in prostate MRI and will discuss the benefits and drawbacks of several new imaging techniques including hybrid multidimensional MRI, low field strength MRI, restriction spectrum imaging, Vascular, Extracellular, and Restricted Diffusion for Cytometry in Tumour (VERDICT) MRI, luminal water imaging, and hyperpolarized C-13 MRI. Additionally, we will introduce several novel AI methods that have been proposed to improve MRI image quality, prostate lesion detection and characterization, as well as touch on the ethical implications of AI in medical imaging of the prostate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.